BartDay
  • Economy
    • Business
    • Politics
  • Cryptocurrency
  • Investing
    • Banking
    • Forex
    • Financial Services
  • Markets
    • Capital Markets
    • Emerging Markets
  • People
    • Consumer & Retail
    • Health
    • Opinion
  • Environment
    • Energy
    • Industrials
    • Manufacturing
  • Technology
    • Learning
    • Auto & Transportation
    • Data
    • Science
    • Telecommunications
  • Featured
  • About
  • Economy
    • Business
    • Politics
  • Cryptocurrency
  • Investing
    • Banking
    • Forex
    • Financial Services
  • Markets
    • Capital Markets
    • Emerging Markets
  • People
    • Consumer & Retail
    • Health
    • Opinion
  • Environment
    • Energy
    • Industrials
    • Manufacturing
  • Technology
    • Learning
    • Auto & Transportation
    • Data
    • Science
    • Telecommunications
  • Featured
  • About
BartDay
BartDay
  • Economy
    • Business
    • Politics
  • Cryptocurrency
  • Investing
    • Banking
    • Forex
    • Financial Services
  • Markets
    • Capital Markets
    • Emerging Markets
  • People
    • Consumer & Retail
    • Health
    • Opinion
  • Environment
    • Energy
    • Industrials
    • Manufacturing
  • Technology
    • Learning
    • Auto & Transportation
    • Data
    • Science
    • Telecommunications
  • Featured
  • About

Second Virus Wave Fears Create Growing Demand for Testing, Treatments and Vaccine Candidates

  • July 13, 2020
  • 4 minute read
Total
0
Shares
0
0
0
0

Coronavirus cases continue to rise in the US this month as regulations lift, causing overambitious governors in several states to backpedal on previous claims. While the rest of the world prepares for a potential second wave, the US continues to struggle to get COVID-19 under control, calling forth urgent demand for rapid tests, treatments, and vaccine candidates. For the last several months, biotech companies big and small have been working to develop solutions to help curb the spread and treat those who have been infected. Vaxart, Inc. (NASDAQ:VXRT) is working on a potential vaccine, while Gilead Sciences Inc (NASDAQ:GILD) is focused on creating a treatment to shorten recovery time for severely ill COVID-19 patients. At the same time, Hologic, Inc. (NASDAQ:HOLX), Roche Holdings (OTCQX:RHHBY), and LexaGene Holdings Inc. (TSXV:LXG) (OTCQB:LXXGF) are creating COVID-19 tests that promise to deliver faster and more accurate results.

WHO Applauds the Efforts of COVID-19 Test Developers

In response to the growing COVID-19 pandemic, along with shortages of laboratory-based molecular testing capacity, numerous biotech companies have developed rapid and easy-to-use devices to facilitate testing outside of laboratory settings. These test kits are based on either the detection of proteins from the COVID-19 virus in respiratory samples or the detection of human antibodies generated in response to infection in a patient’s blood or serum. The World Health Organization (WHO) is applauding the efforts of test developers, but with cases in the US and around the world rising, the need for faster and more accurate tests grows.


Partner with bartday.com. Kindly head here.


From our partners:

CITI.IO :: Business. Institutions. Society. Global Political Economy.
CYBERPOGO.COM :: For the Arts, Sciences, and Technology.
DADAHACKS.COM :: Parenting For The Rest Of Us.
ZEDISTA.COM :: Entertainment. Sports. Culture. Escape.
TAKUMAKU.COM :: For The Hearth And Home.
ASTER.CLOUD :: From The Cloud And Beyond.
LIWAIWAI.COM :: Intelligence, Inside and Outside.
GLOBALCLOUDPLATFORMS.COM :: For The World's Computing Needs.
FIREGULAMAN.COM :: For The Fire In The Belly Of The Coder.
ASTERCASTER.COM :: Supra Astra. Beyond The Stars.
BARTDAY.COM :: Prosperity For Everyone.


On January 27, long before the viral outbreak was labeled a pandemic by the WHO, LexaGene (LXG.V) (LXXGF.QB) addressed how its technology can be used to identify novel pathogens such as coronavirus and the company has continued to make headway in its development.

LexaGene just introduced its new flagship product MiQLab™, a fully automated analyzer that can screen samples for up to 27 different pathogens and/or antimicrobial resistance factors at once and produces results in about one hour.

MiQLab™ offers a set of features not currently available in the market today. In particular, it is open-access, meaning those who currently spend hours manually performing polymerase chain reaction (PCR) because they have custom testing needs, will now be able to have MiQLab run those same tests in a fully automated fashion.

What’s more, LexaGene (LXG.V) (LXXGF.QB) MiQLab technology can be configured to process large volume samples, for extreme sensitivity, which is critical as COVID-19 cases rise.

But, what could really set LexaGene’s COVID-19 tests apart from the rest is the price. According to the press release, the company expects that volume manufacturing will keep the costs for its consumables substantially lower than competing technologies, allowing LexaGene to maintain healthy profit margins even when selling to cost-sensitive markets.

Meanwhile, Swiss multinational healthcare company Roche Holdings (OTCQX:RHHBY) is ramping up the production of its antibody tests to meet ever-growing demand but is having a hard time keeping up. On March 13, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the company’s cobas® SARS-CoV-2 test and the product became widely available in the US and around the world.

Medical technology company Hologic, Inc. (NASDAQ:HOLX) has also developed COVID-19 tests for the growing market and has received EUA from the FDA for two of its products: its Panther Fusion® SARS-CoV-2 test and its Aptima SARS-CoV-2 assay.

Coronavirus Vaccines and Treatments Continue Moving Through Development

Although the world may still be months or potentially years away from a plausible COVID-19 vaccine, the FDA has created a treatment acceleration program to help speed up the process and drugmakers have continued to progress.

Research-based biopharmaceutical company Gilead Sciences Inc (NASDAQ:GILD) is at the forefront of the coronavirus-treatment race after clinical trials of its investigational treatment Remdesivir revealed the drug’s ability to accelerate the recovery of advanced COVID-19. Remdesivir, which is administered through infusions, is the only drug that has been granted EUA from the FDA for the treatment of coronavirus infections.

On June 29, Gilead Sciences Inc  announced a $2,340 price tag for the five-day treatment for people covered by government health programs in the US and other developed countries and $3,120 for those covered by private insurance.

At the forefront of the COVID-19 vaccine initiative is clinical-stage biotechnology company Vaxart, Inc. (NASDAQ:VXRT). The company, which is developing an oral COVID-19 vaccine, has been selected to participate in a non-human primate (NHP) challenge study that is being organized and funded by Operation Warp Speed, the Trump administration’s vaccine-acceleration program aimed to provide substantial quantities of a safe, effective vaccine for Americans by January 2021.

Until a viable vaccine is brought to the market, ongoing demand for rapid COVID-19 tests like LexaGene’s (TSXV:LXG) (OTCQB:LXXGF) MiQLab™ will likely continue as countries across the globe brace for a potential second wave.

For more information on LexaGene (TSXV:LXG) (OTCQB:LXXGF), click here.

 

SOURCE Microsmallcap.com

BartDay

Related Topics
  • coronavirus
  • COVID-19
  • USA
  • Vaccine
You May Also Like
college-of-cardinals-2025
Read More
  • 1 min
  • Featured

The Definitive Who’s Who of the 2025 Papal Conclave

  • May 7, 2025
conclave-poster-black-smoke
Read More
  • 4 min
  • Featured
  • World Events

The World Is Revalidating Itself

  • May 6, 2025
Read More
  • 1 min
  • Featured
  • People

Conclave: How A New Pope Is Chosen

  • April 25, 2025
Read More
  • 4 min
  • Featured
  • World Events

Tariffs, Trump, and Other Things That Start With T – They’re Not The Problem, It’s How We Use Them

  • March 25, 2025
zedreviews-Apple-iPhone-16-Pro-finish-lineup-240909
Read More
  • 12 min
  • Featured
  • Gears
  • Technology

Apple debuts iPhone 16 Pro and iPhone 16 Pro Max

  • September 10, 2024
zedreviews-Apple-iPhone-16-Apple-Intelligence-240909
Read More
  • 12 min
  • Featured
  • Gears
  • Technology

Apple introduces iPhone 16 and iPhone 16 Plus

  • September 10, 2024
zedreviews-Apple-AirPods-Active-Noise-Cancellation-240909
Read More
  • 8 min
  • Featured
  • Gears
  • Technology

Apple introduces AirPods 4 and the world’s first all-in-one hearing health experience with AirPods Pro 2

  • September 10, 2024
zedreviews-Apple-health-2-up-240909
Read More
  • 9 min
  • Featured
  • Gears
  • Technology

Apple introduces groundbreaking health features to support conditions impacting billions of people

  • September 10, 2024
  • The Summer Adventures : Hiking and Nature Walks Essentials
    • June 2, 2025
  • Gemma 3n
    Announcing Gemma 3n preview: powerful, efficient, mobile-first AI
    • May 22, 2025
  • oracle-ibm
    Google Cloud and Philips Collaborate to Drive Consumer Marketing Innovation and Transform Digital Asset Management with AI
    • May 20, 2025
  • college-of-cardinals-2025
    The Definitive Who’s Who of the 2025 Papal Conclave
    • May 7, 2025
  • conclave-poster-black-smoke
    The World Is Revalidating Itself
    • May 6, 2025
about
Unleash Your Financial Potential With Us

BartDay is your all-in source of information for market insights, finance news, investing, trading, and more.

Data and information is provided “as is”. BartDay and any of its information service providers or third party sources is not liable for loss of revenues or profits and damages.

For comments, suggestions, or sponsorships, you may reach us at [email protected]
  • 1
    The Summer Adventures : Hiking and Nature Walks Essentials
    • June 2, 2025
  • Gemma 3n 2
    Announcing Gemma 3n preview: powerful, efficient, mobile-first AI
    • May 22, 2025
  • oracle-ibm 3
    Google Cloud and Philips Collaborate to Drive Consumer Marketing Innovation and Transform Digital Asset Management with AI
    • May 20, 2025
  • college-of-cardinals-2025 4
    The Definitive Who’s Who of the 2025 Papal Conclave
    • May 7, 2025
  • conclave-poster-black-smoke 5
    The World Is Revalidating Itself
    • May 6, 2025
BartDay
  • Economy
  • Cryptocurrency
  • Investing
  • Markets
  • People
  • Environment
  • Technology
  • Featured
  • About
Unleash Your Financial Potential With Us

Input your search keywords and press Enter.